DOI QR코드

DOI QR Code

B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

  • Zhu, Jian (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine) ;
  • Chu, Bing-Feng (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine) ;
  • Yang, Yi-Peng (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine) ;
  • Zhang, Sheng-Lai (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine) ;
  • Zhuang, Ming (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine) ;
  • Lu, Wen-Jie (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine) ;
  • Liu, Ying-Bin (Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University school of Medicine)
  • Published : 2013.05.30

Abstract

Objective: This study aimed to investigate the expression of B7-H4 in human thyroid cancer and determine any association with patient clinicopathological parameters and survival. Methods: B7-H4 expression in 64 clinical thyroid cancer specimens was assessed with immunohistochemistry. Moreover, B7-H4 mRNA expression in 10 fresh resected specimens were evaluated by the reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical staining of CD3 was performed to assess the number of tumor infiltrating T lymphocytes (TILs) in thyroid cancers. Results: Positive B7-H4 immunohistochemical staining was observed in 61 out of 64 (95.3%) specimens of thyroid cancer tissues. Significantly more B7-H4 mRNA copies were found in thyroid cancer tissue than that adjacent normal tissue. Moreover, B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient TNM stages and extrathyroidal extension (P<0.05), being inversely correlated with the number of TILs (P<0.05). The overall survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression. Conclusions: This present study suggests that high B7-H4 expression is associated with cancer progression, reduced tumor immunosurveillance and worse patient outcomes in human thyroid cancer.

References

  1. Xie WC, Chan MH, Mak KC, et al (2012). Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008. Asian Pac J Cancer Prev, 13, 3911-6. https://doi.org/10.7314/APJCP.2012.13.8.3911
  2. Xing M (2013). Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 13, 184-99. https://doi.org/10.1038/nrc3431
  3. Zang X, Loke P, Kim J, et al (2003). B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A, 100, 10388-92. https://doi.org/10.1073/pnas.1434299100
  4. Zhang L, Wu H, Lu D, et al (2013). The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene, Jan 14. doi:10.1038/onc.2012.600. [Epub ahead of print]. https://doi.org/10.1038/onc.2012.600
  5. Zheng X, Li XD, Wu CP, et al (2012). Expression of costimulatory molecule B7-H4 in human malignant tumors. Onkologie, 35, 700-5. https://doi.org/10.1159/000343638
  6. Abadi YM, Jeon H, Ohaegbulam KC, et al (2013). Host b7x promotes pulmonary metastasis of breast cancer. J Immunol, 190, 3806-14. https://doi.org/10.4049/jimmunol.1202439
  7. Arigami T, Uenosono Y, Hirata M, et al (2010). Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol, 102, 748-52. https://doi.org/10.1002/jso.21722
  8. Arigami T, Uenosono Y, Ishigami S, et al (2011). Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg, 35, 2051-7. https://doi.org/10.1007/s00268-011-1186-4
  9. Awadallah NS, Shroyer KR, Langer DA, et al (2008). Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas, 36, 200-6. https://doi.org/10.1097/MPA.0b013e318150e4e0
  10. Chen L (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 4, 336-47. https://doi.org/10.1038/nri1349
  11. Chen LJ, Sun J, Wu HY, et al (2011). B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother, 60, 1047-55. https://doi.org/10.1007/s00262-011-1017-3
  12. Flies DB, Chen L (2007). The new B7s: playing a pivotal role in tumor immunity. J Immunother, 30, 251-60. https://doi.org/10.1097/CJI.0b013e31802e085a
  13. Grabenbauer GG, Lahmer G, Distel L, et al (2006). Tumorinfiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res, 12, 3355-60. https://doi.org/10.1158/1078-0432.CCR-05-2434
  14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  15. Miyatake T, Tringler B, Liu W, et al (2007). B7-H4 (DDO110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol, 106, 119-27. https://doi.org/10.1016/j.ygyno.2007.03.039
  16. Oikonomopoulou K, Li L, Zheng Y, et al (2008). Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer, 99, 1103-13. https://doi.org/10.1038/sj.bjc.6604630
  17. Prasad DV, Richards S, Mai XM, et al (2003). B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity, 18, 863-73. https://doi.org/10.1016/S1074-7613(03)00147-X
  18. Sica GL, Choi IH, Zhu G, et al (2003). B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity, 18, 849-61. https://doi.org/10.1016/S1074-7613(03)00152-3
  19. Siegel R, Naishadham D & Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  20. Sun SQ, Jiang CG, Lin Y, et al (2012). Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines. J Int Med Res, 40, 497-506. https://doi.org/10.1177/147323001204000211
  21. Tringler B, Zhuo S, Pilkington G, et al (2005). B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res, 11, 1842-8. https://doi.org/10.1158/1078-0432.CCR-04-1658
  22. Tuttle RM, Ball DW, Byrd D, et al (2010). Thyroid carcinoma. J Natl Compr Canc Netw, 8, 1228-74.

Cited by

  1. Emerging Co-signaling Networks in T Cell Immune Regulation vol.13, pp.5, 2013, https://doi.org/10.4110/in.2013.13.5.184
  2. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma vol.36, pp.1, 2016, https://doi.org/10.3892/or.2016.4807
  3. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3 vol.276, pp.1, 2017, https://doi.org/10.1111/imr.12521
  4. Potential targeting of B7-H4 for the treatment of cancer vol.276, pp.1, 2017, https://doi.org/10.1111/imr.12530
  5. New checkpoints in cancer immunotherapy vol.276, pp.1, 2017, https://doi.org/10.1111/imr.12524
  6. Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10 vol.66, pp.6, 2017, https://doi.org/10.1007/s00262-017-1961-7